RITUXIMAB‐DOSE‐ADJUSTED EPOCH (R‐DA‐EPOCH) IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL): REAL‐LIFE EXPERIENCE ON 190 PATIENTS FROM 3 MEDITERRANEAN COUNTRIES

Saved in:
Bibliographic Details
Published in:Hematological oncology 2021-06, Vol.39 (S2)
Main Authors: Vassilakopoulos, T., Ferhanoglu, B., Horowitz, N., Mellios, Z., Kaynar, L., Zektser, M., Symeonidis, A., Piperidou, A., Kalpadakis, C., Akay, O. M., Atalar, A. C., Katodritou, E., Leonidopoulou, T., Papageorgiou, S., Tadmor, T., Gutwein, O., Karakatsanis, S., Ganzel, C., Karianakis, G., Isenberg, G., Gainaru, G., Vrakidou, E., Palassopoulou, M., Ozgur, M., Siakantaris, M., Paydas, S., Tsirigotis, P., Tsirogianni, M., Hatzimichael, E., Tuglular, T., Chatzidimitriou, C., Megalakaki, E., Kanellias, N., Zikos, P., Koumarianou, A., Gafter‐Gvili, A., Angelopoulou, M., Karmiris, T., Gurion, R.
Format: Article
Language:English
Subjects:
B-cell lymphoma
Immunotherapy
Lymphoma
Monoclonal antibodies
Rituximab
Targeted cancer therapy
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0278-0232
1099-1069
DOI:10.1002/hon.76_2880